Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory AffairsPRNewsWire • 01/11/22
Cardiff Oncology to Host Conference Call and Webcast to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Being Presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers SymposiumPRNewsWire • 01/10/22
Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual ConferencePRNewsWire • 01/04/22
Cardiff Oncology Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers SymposiumPRNewsWire • 12/10/21
Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth InitiativePRNewsWire • 11/18/21
Cardiff Oncology to Present at Upcoming Jefferies London Healthcare and Piper Sandler 33rd Annual Investor ConferencesPRNewsWire • 11/09/21
Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business UpdatesPRNewsWire • 11/04/21
Will Cardiff Oncology (CRDF) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/28/21
Cardiff Oncology (CRDF) Stock Jumps 7%: Will It Continue to Soar?Zacks Investment Research • 09/14/21
Why Are Investors Cheering Cardiff Oncology's New Data In Colorectal Cancer Setting?Benzinga • 09/09/21
Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free SurvivalPRNewsWire • 09/08/21
Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer on September 8, 2021PRNewsWire • 08/25/21
Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business UpdatesPRNewsWire • 08/05/21
Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/03/21